Perrigo FY2025 EPS Estimate Decreased by Zacks Research

Perrigo Company plc (NYSE:PRGO) – Research analysts at Zacks Research decreased their FY2025 EPS estimates for shares of Perrigo in a research note issued on Wednesday, November 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $2.76 for the year, down from their prior estimate of $2.95. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.76 EPS, Q4 2026 earnings at $0.82 EPS, FY2026 earnings at $2.99 EPS, Q2 2027 earnings at $0.71 EPS, Q3 2027 earnings at $0.80 EPS and FY2027 earnings at $3.16 EPS.

Several other brokerages also recently issued reports on PRGO. Jefferies Financial Group cut their price target on Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a report on Monday, October 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $20.00 target price (down from $32.00) on shares of Perrigo in a research report on Thursday, November 6th. Wall Street Zen cut Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research report on Monday. Finally, Canaccord Genuity Group dropped their price objective on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $22.50.

Perrigo Stock Performance

Shares of PRGO stock opened at $13.62 on Monday. The company has a market cap of $1.87 billion, a P/E ratio of -23.49 and a beta of 0.42. The business has a 50 day moving average of $18.37 and a two-hundred day moving average of $22.92. Perrigo has a 52 week low of $12.17 and a 52 week high of $30.93. The company has a quick ratio of 1.24, a current ratio of 2.32 and a debt-to-equity ratio of 0.81.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the firm earned $0.81 EPS. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS.

Institutional Trading of Perrigo

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Michigan Retirement System boosted its position in shares of Perrigo by 1.2% during the second quarter. State of Michigan Retirement System now owns 33,058 shares of the company’s stock worth $883,000 after purchasing an additional 400 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Perrigo by 54.6% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock valued at $32,000 after buying an additional 424 shares in the last quarter. Amundi raised its stake in Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in Perrigo by 1.4% during the second quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company’s stock worth $1,130,000 after acquiring an additional 564 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its holdings in Perrigo by 1.0% during the second quarter. Harbor Capital Advisors Inc. now owns 57,625 shares of the company’s stock worth $1,540,000 after acquiring an additional 570 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Perrigo

In related news, EVP Abigail Lennox bought 1,255 shares of the stock in a transaction on Monday, September 8th. The shares were purchased at an average price of $22.41 per share, with a total value of $28,124.55. Following the purchase, the executive vice president owned 1,255 shares in the company, valued at approximately $28,124.55. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Geoffrey M. Parker purchased 7,500 shares of Perrigo stock in a transaction dated Wednesday, November 12th. The stock was bought at an average cost of $14.18 per share, with a total value of $106,350.00. Following the completion of the purchase, the director owned 17,375 shares in the company, valued at approximately $246,377.50. This trade represents a 75.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.70% of the company’s stock.

Perrigo Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 16th. Investors of record on Friday, November 28th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, November 28th. This represents a $1.16 annualized dividend and a yield of 8.5%. Perrigo’s dividend payout ratio is presently -305.26%.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.